Double-Blind Randomized Controlled Trial of Acute-Course of Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents
氯胺酮与咪达唑仑治疗青少年自杀复发急性病程的双盲随机对照试验
基本信息
- 批准号:10264146
- 负责人:
- 金额:$ 65.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-15 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:Accident and Emergency departmentAcuteAdolescentAdultAgeAge-YearsCaregiversCaringCause of DeathClinicalClinical TrialsCognitionCognitiveDevelopmentDouble-Blind MethodEmergency department visitEventFamilyFeeling suicidalFemaleGoalsGrantHospitalizationHourImplicit Association TestIndividualInfusion proceduresInpatientsInterventionInterviewIntravenousKetamineKnowledgeLength of StayLinkMeasuresMediatingMediationMedicalMedicineMental DepressionMidazolamParticipantPharmaceutical PreparationsPharmacological TreatmentPharmacologyPharmacotherapyPlacebosProviderPsychotherapyRandomizedRandomized Controlled TrialsRecurrenceReportingResearchRiskSuicideSuicide attemptTestingTimeVisitYouthagedassociated symptombasecare seekingclinical caredepressive symptomseffectiveness trialefficacy evaluationenantiomerexperienceexperimental studyhigh riskinnovationmalenovel therapeuticsopen labeloutpatient programspreventprogramsrecruitreduce symptomsstandard carestandard of caresuicidalsuicidal adolescentsuicidal behaviorsuicidal morbiditysuicidal risksuicide ratesymptomatic improvementtreatment duration
项目摘要
PROJECT SUMMARY
Rates of suicide have increased dramatically in youths over the past decade, and suicide is now the 2nd
leading cause of death for individuals ages 15-24. There are no validated treatments to decrease the risk of
adolescent suicidal behavior, and currently available standard treatments are of modest benefit and often take
weeks or months to become effective. Hence, there is an urgent need to identify rapid-acting treatments that
ameliorate symptoms associated with suicidality and prevent repeat suicidal events. Based on evidence for
efficacy of ketamine in reducing symptoms of suicidality in adults, as well as an open label study in
adolescents, ketamine appears to be a promising treatment approach for youths with a recent suicidal event.
We propose to conduct the first randomized, controlled trial of ketamine in youth with recent suicidal behaviors.
All youth will be in treatment in an intensive outpatient program for suicidal adolescents, and will be
randomized to intravenous ketamine 0.5mg/kg or midazolam 0.02mg/kg for four infusions over two weeks
within +/- ten days of starting IOP. We will also examine implicit cognitive associations using the Death/Suicide
Implicit Association Test (IAT). All participants will be followed for 12 weeks to evaluate: 1) reduction in repeat
suicide attempts over 12 weeks, 2) reduction in implicit suicidal cognition within the 2-week study treatment
period, and 3) reduction in depression and suicidal ideation within the 2-week study period. We will also
explore whether reductions in IAT mediates improvement in suicidality over 12 weeks. To date, no study has
reported evidence for 1) reduction in repeat suicidal events with ketamine either in adults or in youths (AIM 1),
2) reductions either in implicit cognition (AIM 2) or in symptoms associated with suicidality (AIM 3) in youths,
and 3) underlying mechanisms that mediate (AIM 4) the effects of ketamine on suicidality. Innovative features
include: 1) it targets repeat suicidal events during a high-risk period in high-risk youths who are typically
excluded from clinical trials; 2) is transdiagnostic; 3) seamlessly integrates in current standard of care; and 4)
evaluates an intervention that can be delivered at a time and place when there is greatest clinical need, but for
which there are no currently developed interventions.
项目摘要
在过去的十年里,年轻人的自杀率急剧上升,自杀现在是第二大自杀。
是15-24岁人群的主要死因没有有效的治疗方法来降低
青少年自杀行为,目前可用的标准治疗是适度的好处,往往采取
几周或几个月才能生效。因此,迫切需要确定速效治疗方法,
改善与自杀倾向相关的症状并预防重复自杀事件。根据证据,
氯胺酮在减轻成人自杀症状方面的疗效,以及一项在
对于青少年来说,氯胺酮似乎是最近有自杀事件的青少年的一种有希望的治疗方法。
我们建议在近期有自杀行为的年轻人中进行第一次氯胺酮的随机对照试验。
所有的青少年都将在一个针对自杀青少年的强化门诊项目中接受治疗,
随机分配至静脉注射氯胺酮0.5mg/kg或咪达唑仑0.02mg/kg,在两周内输注4次
在开始IOP的+/-10天内。我们还将使用死亡/自杀来检查内隐认知关联
内隐联想测验(IAT)。所有参与者将被随访12周,以评估:1)减少重复
12周内的自杀企图,2)2周研究治疗内的内隐自杀认知减少
3)在2周的研究期内抑郁和自杀意念的减少。我们还将
探索IAT的降低是否介导了12周内自杀倾向的改善。到目前为止,没有任何研究
报告的证据表明:1)氯胺酮在成人或青年中的重复自杀事件减少(AIM 1),
2)内隐认知(AIM 2)或与青年自杀相关的症状(AIM 3)减少,
(3)介导(AIM 4)氯胺酮对自杀行为影响的潜在机制。创新特色
包括:1)它针对高危青少年在高危时期重复自杀事件,这些青少年通常
从临床试验中排除; 2)是跨诊断的; 3)无缝集成在当前的护理标准中;以及4)
评估可以在临床需求最大的时间和地点进行的干预,但
目前还没有开发出干预措施。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MADHUKAR H. TRIVEDI其他文献
MADHUKAR H. TRIVEDI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MADHUKAR H. TRIVEDI', 18)}}的其他基金
Adapted Tele-Behavioral Activation Targeted to Increase Physical Activity in Depression
适应远程行为激活旨在增加抑郁症患者的体力活动
- 批准号:
10194067 - 财政年份:2021
- 资助金额:
$ 65.57万 - 项目类别:
Double-Blind Randomized Controlled Trial of Acute-Course of Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents
氯胺酮与咪达唑仑治疗青少年自杀复发急性病程的双盲随机对照试验
- 批准号:
10114915 - 财政年份:2020
- 资助金额:
$ 65.57万 - 项目类别:
Double-Blind Randomized Controlled Trial of Acute-Course of Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents
氯胺酮与咪达唑仑治疗青少年自杀复发急性病程的双盲随机对照试验
- 批准号:
10471358 - 财政年份:2020
- 资助金额:
$ 65.57万 - 项目类别:
Translational Research Activities in Neuropsychiatry (TRAIN)
神经精神病学转化研究活动(TRAIN)
- 批准号:
9098798 - 财政年份:2014
- 资助金额:
$ 65.57万 - 项目类别:
Translational Research Activities in Neuropsychiatry (TRAIN) - Renewal - 1
神经精神病学转化研究活动 (TRAIN) - 更新 - 1
- 批准号:
10171037 - 财政年份:2014
- 资助金额:
$ 65.57万 - 项目类别:
Translational Research Activities in Neuropsychiatry (TRAIN)
神经精神病学转化研究活动(TRAIN)
- 批准号:
9321772 - 财政年份:2014
- 资助金额:
$ 65.57万 - 项目类别:
Translational Research Activities in Neuropsychiatry (TRAIN)
神经精神病学转化研究活动(TRAIN)
- 批准号:
8741156 - 财政年份:2014
- 资助金额:
$ 65.57万 - 项目类别:
Translational Research Activities in Neuropsychiatry (TRAIN)
神经精神病学转化研究活动(TRAIN)
- 批准号:
8890233 - 财政年份:2014
- 资助金额:
$ 65.57万 - 项目类别:
Translational Research Activities in Neuropsychiatry (TRAIN) - Renewal - 1
神经精神病学转化研究活动 (TRAIN) - 更新 - 1
- 批准号:
10436852 - 财政年份:2014
- 资助金额:
$ 65.57万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 65.57万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 65.57万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 65.57万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 65.57万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 65.57万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 65.57万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 65.57万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 65.57万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 65.57万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 65.57万 - 项目类别:
Operating Grants